aspartic acid has been researched along with Peripheral Nervous System Diseases in 6 studies
Aspartic Acid: One of the non-essential amino acids commonly occurring in the L-form. It is found in animals and plants, especially in sugar cane and sugar beets. It may be a neurotransmitter.
aspartic acid : An alpha-amino acid that consists of succinic acid bearing a single alpha-amino substituent
L-aspartic acid : The L-enantiomer of aspartic acid.
Peripheral Nervous System Diseases: Diseases of the peripheral nerves external to the brain and spinal cord, which includes diseases of the nerve roots, ganglia, plexi, autonomic nerves, sensory nerves, and motor nerves.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Lead poisoning is a medical condition caused by increased levels of the heavy metal lead in the body, generally resulting from environmental exposure." | 1.38 | Guillain-Barré-like syndrome in a child with lead poisoning. ( Craig, F; De Giacomo, A; Del Vecchio, GC; Dicuonzo, F; Margari, L; Petruzzelli, MG; Santoro, N; Toto, M, 2012) |
| "Leprosy is the major cause of non-traumatic neuropathy." | 1.34 | Ninjurin 1 asp110ala single nucleotide polymorphism is associated with protection in leprosy nerve damage. ( Cardoso, CC; de Oliveira, RB; Dias-Neto, E; Guimarães, PE; Illarramendi, X; Martinez, AN; Mendes, CT; Moraes, MO; Pacheco, AG; Sampaio, EP; Sarno, EN; Teles, RM, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (16.67) | 18.2507 |
| 2000's | 3 (50.00) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lavigne Moreira, C | 1 |
| Marques, VD | 1 |
| Lourenço, CM | 1 |
| Cabrini, DI | 1 |
| Nuñez, JC | 1 |
| Herrera, RF | 1 |
| Marques, W | 1 |
| Toto, M | 1 |
| De Giacomo, A | 1 |
| Petruzzelli, MG | 1 |
| Dicuonzo, F | 1 |
| Santoro, N | 1 |
| Del Vecchio, GC | 1 |
| Craig, F | 1 |
| Margari, L | 1 |
| Cardoso, CC | 1 |
| Martinez, AN | 1 |
| Guimarães, PE | 1 |
| Mendes, CT | 1 |
| Pacheco, AG | 1 |
| de Oliveira, RB | 1 |
| Teles, RM | 1 |
| Illarramendi, X | 1 |
| Sampaio, EP | 1 |
| Sarno, EN | 1 |
| Dias-Neto, E | 1 |
| Moraes, MO | 1 |
| Cui, JG | 1 |
| O'Connor, WT | 1 |
| Ungerstedt, U | 1 |
| Linderoth, B | 1 |
| Meyerson, BA | 1 |
| Mertens, P | 1 |
| Ghaemmaghami, C | 1 |
| Bert, L | 1 |
| Perret-Liaudet, A | 1 |
| Sindou, M | 1 |
| Renaud, B | 1 |
| Somers, DL | 1 |
| Clemente, FR | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Single Blinded, Randomized Control Trial of High Frequency Stimulation in Subjects With Precision® Spinal Cord Stimulator System to Assess Efficacy and Preferability in Back and Extremity Pain Relief[NCT02265848] | Phase 4 | 22 participants (Actual) | Interventional | 2014-10-31 | Completed | ||
| Identification of Differentially Expressed Genes in RNAseq Data of Patients With Failed Back Surgery Syndrome Treated With Different Modalities of Spinal Cord Stimulation: Looking for Biomarkers of Response and Effectiveness[NCT05712980] | 40 participants (Anticipated) | Observational | 2023-02-28 | Not yet recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Digital pain rating system that scores patient's subjective pain rating from 0 to 10; with greater number indicating progressively worsening pain. NPRS were measured at baseline (visit1), and at each follow ups visits at visit 2, 3 and 4. Visit 2 and 4 captured post treatment (either 1000 Hz or standard stimulation depending on the randomization) results, and visit 3 captured NPRS after the wash off from the spinal cord stimulation. (NCT02265848)
Timeframe: Baseline (visit 1), and at each follow up visits (visits 2, 3, and 4)
| Intervention | units on a scale (Mean) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Average Baseline NPRS Score | Average NPRS after 1000 Hz. stimulation | Average NPRS after standard stimulation | Average NPRS after Wash off | Best Baseline NPRS score | Best NPRS score after 1000 Hz. stimulation | Best NPRS score after standard stimulation | Best NPRS after Wash off | Worst Baseline NPRS score | Worst NPRS score after 1000 Hz. stimulation | Worst NPRS score after standard stimulation | Worst NPRS after Wash off | |
| Treatment Group A | 6.09 | 3.73 | 5.64 | 6.45 | 3.72 | 2.64 | 3.46 | 4.54 | 7.90 | 6.64 | 8.18 | 8.72 |
| Treatment Group B | 6.27 | 3.82 | 6.09 | 7.18 | 4.45 | 2.18 | 4.45 | 5.36 | 8.09 | 6.64 | 8.36 | 8.81 |
ODI is a outcome metrics that is design to assess the severity of disability based on 10 activity categories. ODI is based on 0 to 100% scale, where larger percentage implies worse disability. (There are 5 categories: 0-20%: Minimal disability, 21-40%: Moderate disability, 41-60%: Severe disability, 61-80%: Crippled. 81-100%: Either bed bound or exaggerating symptoms). ODI were measured at baseline (visit1), and at each follow ups visits at visit 2, 3 and 4. Visit 2 and 4 captured post treatment (either 1000 Hz or standard stimulation depending on the randomization) results, and visit 3 captured NPRS after the wash off from the spinal cord stimulation. (NCT02265848)
Timeframe: Baseline (visit 1), and at each follow up visits (visits 2, 3, and 4)
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| Baseline ODI score | ODI after 1000 Hz. stimluation | ODI after standard stimulation | ODI after wash off | |
| Treatment Group A | 47.49 | 39.23 | 49.63 | 52.87 |
| Treatment Group B | 51.25 | 33.77 | 49.05 | 56.77 |
PGIC is a 7-point scale that requires study subjects to rate the severity of their illness or medical condition after a specific treatment. 1: No change, 2: Almost the same, 3: A little better, 4: Somewhat better, 5: Moderately better, 6: Better, 7: A great deal better. Study subjects were asked to report their impression of changes at baseline visit, visit 2 through 4. (NCT02265848)
Timeframe: Baseline (visit 1), and at each follow up visits (visits 2, 3, and 4)
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| PGIC After 1000 Hz. stimulation | PGIC after standard stimulation | PGIC after Wash off | |
| Treatment Group A | 4.27 | 2.54 | 1.45 |
| Treatment Group B | 5.91 | 2.45 | 1.27 |
At the conclusion of the study, subjects were asked to report which spinal cord stimulation modes they preferred. Subjects were presented with two boxes (1000 Hz. stimulation and Standard stimulation) and asked to check one. (NCT02265848)
Timeframe: End of treatment visit on visit 4
| Intervention | participants (Number) | |
|---|---|---|
| Subjects who prefer 1000 Hz. stimulation | Subjects who prefer standard stimulation | |
| Treatment Group A | 8 | 3 |
| Treatment Group B | 10 | 1 |
6 other studies available for aspartic acid and Peripheral Nervous System Diseases
| Article | Year |
|---|---|
Transthyretin Asp38Tyr: a new mutation associated to a late onset neuropathy.
Topics: Aged; Aspartic Acid; Female; Humans; Mutation; Peripheral Nervous System Diseases; Prealbumin; Tyros | 2015 |
Guillain-Barré-like syndrome in a child with lead poisoning.
Topics: Anemia; Aspartic Acid; Brain; Child, Preschool; Choline; Female; Guillain-Barre Syndrome; Humans; Le | 2012 |
Ninjurin 1 asp110ala single nucleotide polymorphism is associated with protection in leprosy nerve damage.
Topics: Adult; Alanine; Amino Acid Substitution; Aspartic Acid; Cell Adhesion Molecules, Neuronal; DNA Mutat | 2007 |
Spinal cord stimulation attenuates augmented dorsal horn release of excitatory amino acids in mononeuropathy via a GABAergic mechanism.
Topics: Animals; Aspartic Acid; Electric Stimulation; Excitatory Amino Acids; GABA Agents; GABA-A Receptor A | 1997 |
Spinal cord stimulation attenuates augmented dorsal horn release of excitatory amino acids in mononeuropathy via a GABAergic mechanism.
Topics: Animals; Aspartic Acid; Electric Stimulation; Excitatory Amino Acids; GABA Agents; GABA-A Receptor A | 1997 |
Spinal cord stimulation attenuates augmented dorsal horn release of excitatory amino acids in mononeuropathy via a GABAergic mechanism.
Topics: Animals; Aspartic Acid; Electric Stimulation; Excitatory Amino Acids; GABA Agents; GABA-A Receptor A | 1997 |
Spinal cord stimulation attenuates augmented dorsal horn release of excitatory amino acids in mononeuropathy via a GABAergic mechanism.
Topics: Animals; Aspartic Acid; Electric Stimulation; Excitatory Amino Acids; GABA Agents; GABA-A Receptor A | 1997 |
Amino acids in spinal dorsal horn of patients during surgery for neuropathic pain or spasticity.
Topics: Amino Acids; Aspartic Acid; Chromatography, High Pressure Liquid; Extracellular Space; Feasibility S | 2000 |
Dorsal horn synaptosomal content of aspartate, glutamate, glycine and GABA are differentially altered following chronic constriction injury to the rat sciatic nerve.
Topics: Age Factors; Animals; Aspartic Acid; Causalgia; Down-Regulation; gamma-Aminobutyric Acid; Glutamic A | 2002 |